Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Objective: This study aimed to evaluate the association between metformin treatment and the risk of neurodegenerative disease (ND) among elderly adults with type 2 diabetes mellitus (T2DM). Design/Setting/Participants: This retrospective longitudinal cohort study examined the effects of the length of metformin exposure on ND among elderly US veterans with T2DM and insulin treatment using the Veterans Affairs electronic medical record database. Primary and secondary outcome measures: The primary clinical outcome was defined as diagnosis of ND including dementia, Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD) and mild cognitive impairment during the follow-up period. The secondary clinical outcomes were separately measured by AD, PD, HD, dementia and mild cognitive impairment. Result: Adjusted by propensity score weight, a total of 5528 patients (mean age, 63.2±10.9 years; male, 98%; white, 60%) with a median follow-up of 5.2 years were selected. Those with ND or other mental disorders at baseline or who were on insulin for less than two-thirds of the study period were excluded. The incidence rate of ND was 11.48 per 1000 person-years among patients with metformin treatment, compared with 25.45 per 1000 person-years for those without metformin. Compared with no metformin use, 2–4 years and >4 years of metformin exposure were significantly associated with lower risk of ND (adjusted HR (aHR)=0.62, 95% CI 0.45 to 0.85; aHR=0.19, 95% CI 0.12 to 0.31, respectively), while metformin exposure in the first 2 years showed no significant influence. Conclusion: We conclude that long-term metformin therapy (>2 years) was associated with lower incidence of ND among elderly veterans with T2DM. We need to conduct a study with more representative population and more robust method for causal inferences. Further investigation into the mechanism involved is needed along with randomised trials to confirm a potential neuroprotective effect of metformin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“several clinical studies suggest that long-term metformin therapy is associated with a lower risk of neurodegenerative diseases.524,525”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [524]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Moreira, R. O., Campos, S. C., & Soldera, A. L. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2442 · Cited by 32
Retracted2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
Diabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871
Monetary Costs of Dementia in the United States
Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1204629 · Cited by 1,484 · cited 1×
“Additionally, costs were estimated at $157–$215 billion in 2010.(5) Type 2 diabetes mellitus (T2DM) is found to precipitate the burden of ND by increasing the risk of all types of dementia, AD and mild cognitive impairment by about 1.”
How common are the "common" neurologic disorders?
Hirtz, D., Thurman, D. J., Gwinn-Hardy, K., Mohamed, M., Chaudhuri, A. R., & Zalutsky, R. (2007) · Neurology · doi:10.1212/01.wnl.0000252807.38124.a3 · Cited by 1,365
HOW COMMON ARE THE “COMMON” NEUROLOGIC DISORDERS?
Kaplin, A. I., & Williams, M. (2007) · Neurology · doi:10.1212/01.wnl.0000278071.91524.4d · Cited by 1,131
Cheng, G., Huang, C., Deng, H., & Wang, H. (2012) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2012.02758.x · Cited by 1,040
Diabetes and cognitive dysfunction
McCrimmon, R. J., Ryan, C. M., & Frier, B. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60360-2 · Cited by 880
Diabetes mellitus and risk of dementia: A meta‐analysis of prospective observational studies
Gudala, K., Bansal, D., Schifano, F., & Bhansali, A. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12087 · Cited by 727
Chatterjee, S., Peters, S. A. E., Woodward, M., Mejia Arango, S., Batty, G. D., Beckett, N., Beiser, A., Borenstein, A. R., Crane, P. K., Haan, M., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1588 · Cited by 711
2010 Alzheimer's disease facts and figures
Alzheimer's Association (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.01.009 · Cited by 684
The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia: Two Roads Converged
Craft, S. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.27 · Cited by 547
Wang, J., Gallagher, D., DeVito, L. M., Cancino, G. I., Tsui, D., He, L., Keller, G. M., Frankland, P. W., Kaplan, D. R., & Miller, F. D. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.03.016 · Cited by 474
Imfeld, P., Bodmer, M., Jick, S. S., & Meier, C. R. (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2012.03916.x · Cited by 388
Hsu, C.-C., Wahlqvist, M. L., Lee, M.-S., & Tsai, H.-N. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101524 · Cited by 372
Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?
Akter, K., Lanza, E. A., Martin, S. A., Myronyuk, N., Rua, M., & Raffa, R. B. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03830.x · Cited by 352
Increased risk of cognitive impairment in patients with diabetes is associated with metformin
Moore, E. M., Mander, A. G., Ames, D., Kotowicz, M. A., Carne, R. P., Brodaty, H., Woodward, M., Boundy, K., Ellis, K. A., Bush, A. I., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0229 · Cited by 349
Long-Term Metformin Usage and Cognitive Function among Older Adults with Diabetes
Ng, T. P., Feng, L., Yap, K. B., Lee, T. S., Tan, C. H., & Winblad, B. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-131901 · Cited by 334
MacKnight, C., Rockwood, K., Awalt, E., & McDowell, I. (2002) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000064928 · Cited by 313
Estimation of the causal effects of time-varying exposures
Robins, J., & Hernan, M. (2008) · Chapman & Hall/CRC Handbooks of Modern Statistical Methods · doi:10.1201/9781420011579.ch23 · Cited by 312
Gupta, A., Bisht, B., & Dey, C. S. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.033 · Cited by 302
Link between type 2 diabetes and Alzheimer’s disease: from epidemiology to mechanism and treatment
Li, X., Leng, S., & Song, D. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s74042 · Cited by 292
Improving Metabolic Control Leads to Better Working Memory in Adults With Type 2 Diabetes
Ryan, C. M., Freed, M. I., Rood, J. A., Cobitz, A. R., Waterhouse, B. R., & Strachan, M. W. J. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1626 · Cited by 289
Bosco, D., Fava, A., Plastino, M., Montalcini, T., & Pujia, A. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01318.x · Cited by 283
Biessels, G. J., & Kappelle, L. J. (2005) · Biochemical Society Transactions · doi:10.1042/bst0331041 · Cited by 266
Cognitive dysfunction in patients with type 2 diabetes
Reijmer, Y. D., van den Berg, E., Ruis, C., Jaap Kappelle, L., & Biessels, G. J. (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1112 · Cited by 251
El-Mir, M.-Y., Detaille, D., R-Villanueva, G., Delgado-Esteban, M., Guigas, B., Attia, S., Fontaine, E., Almeida, A., & Leverve, X. (2008) · Journal of Molecular Neuroscience · doi:10.1007/s12031-007-9002-1 · Cited by 244
Wahlqvist, M. L., Lee, M.-S., Hsu, C.-C., Chuang, S.-Y., Lee, J.-T., & Tsai, H.-N. (2012) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.03.010 · Cited by 233
Desai, N. R., Shrank, W. H., Fischer, M. A., Avorn, J., Liberman, J. N., Schneeweiss, S., Pakes, J., Brennan, T. A., & Choudhry, N. K. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.07.033 · Cited by 149
Metformin Protects the Brain Against the Oxidative Imbalance Promoted by Type 2 Diabetes
Correia, S., Carvalho, C., Santos, M., Proenca, T., Nunes, E., Duarte, A., Monteiro, P., Seica, R., Oliveira, C., & Moreira, P. (2008) · Medicinal Chemistry · doi:10.2174/157340608784872299 · Cited by 110
Recent Antihyperglycemic Prescribing Trends for U.S. Privately Insured Patients With Type 2 Diabetes
Cohen, F. J., Neslusan, C. A., Conklin, J. E., & Song, X. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1847 · Cited by 107
Mielke, J. G., Taghibiglou, C., & Wang, Y. T. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.07.055 · Cited by 89
Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide
Candeias, E. M. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i6.807 · Cited by 83
Parkinson disease: primacy of age as a risk factor for mitochondrial dysfunction
VanItallie, T. B. (2008) · Metabolism · doi:10.1016/j.metabol.2008.07.015 · Cited by 75
Dementia in the USA: state variation in prevalence
Koller, D., & Bynum, J. P. W. (2014) · Journal of Public Health · doi:10.1093/pubmed/fdu080 · Cited by 68
Alzheimer's Disease and Diabetes: New Insights and Unifying Therapies
Vignini, A., Giulietti, A., Nanetti, L., Raffaelli, F., Giusti, L., Mazzanti, L., & Provinciali, L. (2013) · Current Diabetes Reviews · doi:10.2174/1573399811309030003 · Cited by 58
Type 2 diabetes, cognitive function and dementia: Vascular and metabolic determinants
van den Berg, E., Kessels, R. P. C., Kappelle, L. J., de Haan, E. H. F., & Biessels, G. J. (2006) · Drugs of Today · doi:10.1358/dot.2006.42.11.1003542 · Cited by 47
Hypoglycaemia and dementia in diabetic patients
Bauduceau, B., Doucet, J., Bordier, L., Garcia, C., Dupuy, O., & Mayaudon, H. (2010) · Diabetes & Metabolism · doi:10.1016/s1262-3636(10)70476-6 · Cited by 46
Hwang, I. K., Kim, I. Y., Joo, E. J., Shin, J. H., Choi, J. W., Won, M., Yoon, Y. S., & Seong, J. K. (2010) · Neurochemical Research · doi:10.1007/s11064-009-0115-5 · Cited by 43
Metformin in the diabetic brain: friend or foe?
Moreira, P. I. (2014) · PubMed · doi:10.3978/j.issn.2305-5839.2014.06.10 · Cited by 34
Cognitive disorders in diabetic patients
Koekkoek, P. S., Rutten, G. E. H. M., & Biessels, G. J. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53480-4.00011-4 · Cited by 28
Trinkley, K. E., Malone, D. C., Nelson, J. A., & Saseen, J. J. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622316657328 · Cited by 15
(2013) · PubMed
Cited by
Xian, H., Liu, Y., Rundberg Nilsson, A., Gatchalian, R., Crother, T. R., Tourtellotte, W. G., Zhang, Y., Aleman-Muench, G. R., Lewis, G., Chen, W., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.05.004 · Cited by 407
Metformin: Is it a drug for all reasons and diseases?
Triggle, C. R., Mohammed, I., Bshesh, K., Marei, I., Ye, K., Ding, H., MacDonald, R., Hollenberg, M. D., & Hill, M. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155223 · Cited by 275
Storm, C. S., Kia, D. A., Almramhi, M. M., Bandres-Ciga, S., Finan, C., International Parkinson’s Disease Genomics Consortium (IPDGC), Noyce, A. J., Kaiyrzhanov, R., Middlehurst, B., Tan, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26280-1 · Cited by 208
Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., Gupta, D., & Edison, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101979 · Cited by 179
“In 5528 patients with T2DM, long-term metformin use ( > 2 years) significantly reduced the risk of developing neurodegenerative disorders including dementia, AD, PD, Huntington ’ s disease, and MCI with a median follow-up period of 5.2 years (Shi et al., 2019).”
BackgroundInfluentialAntiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165
Metadata
- Authors
- Shi, Q., Liu, S., Fonseca, V. A., Thethi, T. K., & Shi, L.
- Affiliations
- Tulane University (US)
- Corresponding author
- Shi, Lizheng
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2019-07
- Volume
- 9
- Issue
- 7
- Pages
- e024954
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC6677947
- OpenAlex
- W2964394554
- Cited by
- 144
- References
- 49
- Citations by year
- 2026: 11 · 2025: 21 · 2024: 18 · 2023: 33 · 2022: 28 · 2021: 15 · 2020: 17 · 2019: 1
- FWCI
- 12.12
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- National Institute of General Medical Sciences (U54GM104940)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- metformin, neurodegenerative diseases, type 2 diabetes, veterans, Alzheimer's disease, Parkinson's disease, Huntington's disease, dementia, mild cognitive impairment, insulin therapy, neuroprotection, drug exposure duration
- MeSH terms
- Aged, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Longitudinal Studies, Male, Metformin, Middle Aged, Retrospective Studies, Risk Factors, United States, Veterans, Comorbidity, Incidence, Proportional Hazards Models, Neurodegenerative Diseases, Propensity Score
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.